Treatment of malignant pleural mesothelioma: current status and future directions

https://doi.org/10.4081/monaldi.2010.302

Authors

  • X. Dhalluin University of Lille II, Medical School Henri Warembourg, Lille, France.
  • A. Scherpereel | arnaud.scherpereel@chru-lille.fr University of Lille II, Medical School Henri Warembourg, Lille, France.

Abstract

Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumour that has become a very important issue over recent years due to its poor prognosis and its increasing incidence mostly linked to previous asbestos exposure. An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. Thus the aim of this review is to provide clinicians clear and up-to-dated data on the latest therapeutic strategies for MPM patients in 2010. The guidelines recently proposed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) taskforce are summarized here. The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2016-01-19
Info
Issue
Section
Reviews
Statistics
  • Abstract views: 391

  • PDF: 359
How to Cite
Dhalluin, X., and A. Scherpereel. 2016. “Treatment of Malignant Pleural Mesothelioma: Current Status and Future Directions”. Monaldi Archives for Chest Disease 73 (2). https://doi.org/10.4081/monaldi.2010.302.

Most read articles by the same author(s)